{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:58:20Z","timestamp":1786993100295,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jogc.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jogc.2022.10.012","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T20:56:25Z","timestamp":1667940985000},"page":"1279-1288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and Safety of Oral GnRh Antagonists in Patients With Uterine Fibroids: A Systematic Review"],"prefix":"10.1016","volume":"44","author":[{"given":"Rabiya","family":"Niaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Memoona","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5586-6280","authenticated-orcid":false,"given":"Muhammad Ashar","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Irshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marium","family":"Faiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Irshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraeha","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer Altaf","family":"Tunio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajeeha","family":"Aiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jogc.2022.10.012_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jogc.2022.10.012_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.fertnstert.2010.08.049","article-title":"Proceedings from the national institute of child health and human development conference on the uterine fibroid research update workshop","volume":"95","author":"Catherino","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogc.2022.10.012_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2008.12.037","article-title":"Magnetic resonance imaging and transvaginal ultrasound for determining fibroid burden: implications for research and clinical care","volume":"200","author":"Levens","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jogc.2022.10.012_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ijgo.13102","article-title":"Epidemiology and management of uterine fibroids","volume":"149","author":"Giuliani","year":"2020","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jogc.2022.10.012_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.jogc.2022.10.012_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1258\/mi.2012.012008","article-title":"Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update","volume":"18","author":"McLaren","year":"2012","journal-title":"Menopause Int"},{"key":"10.1016\/j.jogc.2022.10.012_bib7","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.6189.1","article-title":"Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management","author":"Taylor","year":"2015","journal-title":"F1000Res"},{"key":"10.1016\/j.jogc.2022.10.012_bib8","author":"Agency"},{"key":"10.1016\/j.jogc.2022.10.012_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bpobgyn.2015.11.016","article-title":"Role of medical management for uterine leiomyomas","volume":"34","author":"Kashani","year":"2016","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.jogc.2022.10.012_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/TCRM.S147318","article-title":"Uterine fibroids: an update on current and emerging medical treatment options","volume":"15","author":"Farris","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jogc.2022.10.012_bib11","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1021\/jm8006454","volume":"51","author":"Chen","year":"2008","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jogc.2022.10.012_bib12","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1021\/jm200216q","volume":"54","author":"Miwa","year":"2011","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jogc.2022.10.012_bib13","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Chandler","year":"2019"},{"key":"10.1016\/j.jogc.2022.10.012_bib14","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jogc.2022.10.012_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.jogc.2022.10.012_bib16","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jogc.2022.10.012_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jogc.2022.10.012_bib18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jogc.2022.10.012_bib19","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1097\/01.AOG.0000662956.14857.59","article-title":"Up to 12 months of elagolix sustained menstrual blood loss reduction in women with uterine fibroids","volume":"135","author":"Simon","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2022.10.012_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","article-title":"Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial","volume":"133","author":"Osuga","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2022.10.012_bib21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.fertnstert.2019.07.013","article-title":"Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women","volume":"112","author":"Osuga","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogc.2022.10.012_bib22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.fertnstert.2017.05.006","article-title":"Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study","volume":"108","author":"Archer","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogc.2022.10.012_bib23","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/AOG.0000000000002933","article-title":"Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial","volume":"132","author":"Carr","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2022.10.012_bib24","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1016\/j.fertnstert.2020.09.016","article-title":"Efficacy and safety of linzagolix (LGX) for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids (UF): results from two phase 3 randomized clinical trials","volume":"114","author":"Stewart","year":"2020","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogc.2022.10.012_bib25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.fertnstert.2020.08.027","article-title":"LIBERTY: long-term extension study demonstrating one-year efficacy and safety of relugolix combination therapy in women with symptomatic uterine fibroids","volume":"114","author":"Al-Hendy","year":"2020","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogc.2022.10.012_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmig.2018.09.175","article-title":"Efficacy and safety of elagolix in a subgroup of women with uterine fibroids and adenomyosis: results from a phase 2 trial","volume":"25","author":"Taylor","year":"2018","journal-title":"J\u00a0Minim Invasive Gynecol"},{"issue":"4 Pt 1","key":"10.1016\/j.jogc.2022.10.012_bib27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/0002-9378(90)90667-V","article-title":"Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis","volume":"163","author":"Friedman","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jogc.2022.10.012_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/00016348509155136","article-title":"Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium","volume":"64","author":"Tamaya","year":"1985","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jogc.2022.10.012_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1210\/jc.2008-1695","article-title":"Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix","volume":"94","author":"Struthers","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jogc.2022.10.012_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2013.12.001","article-title":"Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice","volume":"723","author":"Nakata","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jogc.2022.10.012_bib31","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/j.fertnstert.2019.08.012","article-title":"Treatment of symptoms of uterine fibroids with relugolix combination therapy: efficacy and safety results from the phase 3 liberty 1 clinical trial","volume":"112","author":"Al-Hendy","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogc.2022.10.012_bib32","first-page":"CD000547","article-title":"Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids","volume":"2","author":"Lethaby","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jogc.2022.10.012_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5468\/ogs.2018.61.2.192","article-title":"Current medical treatment of uterine fibroids","volume":"61","author":"Sohn","year":"2018","journal-title":"Obst Gynecol Sci"},{"key":"10.1016\/j.jogc.2022.10.012_bib36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/nu12010202","article-title":"Menopause-associated lipid metabolic disorders and foods beneficial for postmenopausal women","volume":"12","author":"Ko","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.jogc.2022.10.012_bib37","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwp043","article-title":"Lipid changes during the menopause transition in relation to age and weight: the study of women's health across the nation","volume":"169","author":"Derby","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jogc.2022.10.012_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000002675","article-title":"Long-term outcomes of elagolix in women with endometriosis: results from two extension studies","volume":"132","author":"Surrey","year":"2018","journal-title":"Obstet Gynecol"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216322006843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216322006843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:40:42Z","timestamp":1761666042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1701216322006843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1701216322006843"],"URL":"https:\/\/doi.org\/10.1016\/j.jogc.2022.10.012","relation":{},"ISSN":["1701-2163"],"issn-type":[{"value":"1701-2163","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Oral GnRh Antagonists in Patients With Uterine Fibroids: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2022.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Society of Obstetricians and Gynaecologists of Canada\/La Soci\u00e9t\u00e9 des obst\u00e9triciens et gyn\u00e9cologues du Canada. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}